ReviewChildren (Basel, Switzerland)2022
Erythema Nodosum in Children: A Narrative Review and a Practical Approach.
Review in Children (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Unexpected erythema nodosum during dupilumab treatment for severe asthma: Causal or casual?JAAD case reports · 2026Article
- Pediatric Plantar Erythema Nodosum Associated with Beta-Hemolytic Streptococcal Infection: A Rare condition.Dermatology practical & conceptual · 2026Article
- Celiac Disease Presenting With Erythema Nodosum in a Child: Case Report and Review of the Literature.Case reports in pediatrics · 2026Article
- Erythema nodosum as a rare presentation of pulmonary tuberculosis in adolescents: A case report.Respiratory medicine case reports · 2026Article
- Erythema Nodosum Associated with Kerion: A Case Series and Narrative Review of the Literature.Journal of fungi (Basel, Switzerland) · 2025Article
- Erythema nodosum in northern Finland between 1996 and 2019: A register-based study.The Journal of dermatology · 2024Article
- Erythema nodosum in children: a cohort study from a tertiary pediatric hospital in Italy.European journal of pediatrics · 2023Observational
- Erythema nodosum triggered by kerion celsi in pediatrics: literature review and case report.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythema nodosum (EN) is the most frequent form of panniculitis in children. We performed a literature review analyzing studies on pediatric EN published from 1990 to February 2022. EN is rare in pediatric age. It can be primary/idiopathic in 23-55% cases, or secondary in 47-77% cases. Secondary EN is related to a wide variety of conditions including infectious diseases, autoimmune disorders, malignancy, drugs, vaccinations, and pregnancy. The diagnosis of EN is clinical, based on the acute appearance of painful and red nodules localized to lower limbs, bilaterally distributed. If EN is diagnosed, basic work-up should include inflammatory markers, serum aminotransferases, lactate dehydrogenase, creatinine, protein electrophoresis, immunoglobulins, testing for streptococcal infection, and a tuberculin skin test. Based on the medical history and associated manifestations, further laboratory and radiological exams should be performed. The prognosis of EN is excellent, with spontaneous resolution in most patients within 2-6 weeks. Treatment, if needed, is addressed to the underlying condition. Despite being a rare manifestation in children, EN can be isolated or the first manifestation of a systemic or infectious condition. EN diagnosis is clinical, and a high index of suspicion is needed to perform investigations for the underlying disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.